In an editorial comment about the study, a leukemia expert from Johns Hopkins University in Baltimore said the use of imatinib and similar agents "create a platform from which we can entertain the possibility of curing" the disease without a stem cell transplant. B. Douglas Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center, called for research on ways to completely eliminate the small amount of residual disease after treatment with imatinib. “It is now time for clinical and laboratory investigators to build on this platform and work to turn good and great responses into cures," he added.
Gambacorti-Passerini C, Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. Journal of the National Cancer Institute, 2011;103(7):553-561. http://jnci.oxfordjournals.org/content/103/7/553.short?rss=1
Smith, B. Douglas, MD, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Correspondence, Journal of the National Cancer Institute, 201,103 (7): NP. doi: 10.1093/jnci/djr127 http://jnci.oxfordjournals.org/content/103/7/527.full
National Cancer Institute: Gleevec Questions and Answers: http://www.cancer.gov/newscenter/qa/2001/gleevecqa
National CML Society: CML Therapies: http://www.nationalcmlsociety.org/living-cml/therapies